c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

PURPOSE: Strategies to inhibit the epidermal growth factor receptor (EGFR) using the tyrosine kinase inhibitor (TKI) erlotinib have been associated with limited clinical efficacy in head and neck squamous cell carcinoma (HNSCC). Co-activation of alternative kinases may contribute to erlotinib resist...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stabile, Laura P., He, Guoqing, Lui, Vivian Wai Yan, Henry, Cassandra, Gubish, Christopher T., Joyce, Sonali, Quesnelle, Kelly, Siegfried, Jill M., Grandis, Jennifer R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549019/
https://ncbi.nlm.nih.gov/pubmed/23213056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1555
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados